Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $87
Wedbush analyst David Nierengarten maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and raises the price target from $73 to $87.
Barclays Maintains Overweight on Intellia Therapeutics, Raises Price Target to $134
Barclays analyst Gena Wang maintains Intellia Therapeutics (NASDAQ:NTLA) with a Overweight and raises the price target from $88 to $134.
Goldman Sachs Maintains Buy on Intellia Therapeutics, Raises Price Target to $163
Goldman Sachs analyst Salveen Richter maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and raises the price target from $115 to $163.
Truist Securities Maintains Buy on Intellia Therapeutics, Raises Price Target to $160
Truist Securities analyst Joon Lee maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and raises the price target from $80 to $160.
Roth Capital Maintains Buy on Intellia Therapeutics, Raises Price Target to $110
Roth Capital analyst Tony Butler maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and raises the price target from $80 to $110.
Intellia Shares Shoot Higher On Promising Biomarker Data From CRISPR/Cas9 Genome Editing Candidate
Intellia Therapeutics Inc (NASDAQ:NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have announced positive interim data from an ongoing Phase 1 study of NTLA-2001, which…
Chardan Capital Maintains Buy on Intellia Therapeutics, Raises Price Target to $130
Chardan Capital analyst Geulah Livshits maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and raises the price target from $85 to $130.